Home › NDC Lookup › RxCUI directory › RxCUI 197501

Chlorzoxazone 250 MG Oral Tablet — RxCUI 197501

RxNorm drug concept · Semantic clinical drug
RxCUI 197501 Semantic clinical drug · SCD ● Current RxNorm concept 6 FDA products 11 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI197501
Official nameChlorzoxazone 250 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped6
Package NDCs mapped11
Reported Medicaid activity (SDUD)10,111 prescriptions · 9 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Chlorzoxazone: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Chlorzoxazone is a muscle relaxant used to help with short-term muscle pain and spasms — the kind that comes on suddenly from an injury or strain. It's meant to be used together wi...
  • Yes, drowsiness and dizziness are real possibilities with chlorzoxazone. Until you know how it affects you, it's best to avoid driving or operating machinery. Alcohol makes the dro...
  • Will this make me drowsy? Is it safe to drive?
  • This is actually a known and harmless side effect. Chlorzoxazone breaks down into a substance that can temporarily color your urine orange or reddish-brown. It has no known clinica...
📖 Read our full Chlorzoxazone guide →

🕸️ Concept Web — How Chlorzoxazone 250 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Chlorzoxazone 250 MG Oral Tablet RxCUI 197501

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Chlorzoxazone 2410
  2. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Chlorzoxazone Oral Tablet 371473
    • Chlorzoxazone Oral Product 1155809
    • Chlorzoxazone Pill 1155810
    • Oral Tablet 317541
    • Oral Product 1151131
    • Pill 1151133
  3. Clinical & branded drugs 1

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Chlorzoxazone 250 MG 315656

Showing up to 8 concepts per family — 8 of 8 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Chlorzoxazone 250 MG SCDC · 315656
  • Chlorzoxazone Oral Tablet SCDF · 371473
  • Chlorzoxazone Oral Product SCDG · 1155809
  • Chlorzoxazone Pill SCDG · 1155810

📦 FDA Products & Package NDCs

6 products · 11 package NDCs
11 package NDCs map to RxCUI 197501 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
24470-0923-10 100 TABLET in 1 BOTTLE (24470-923-10) CHLORZOXAZONE Cintex Services, LLC 2021-09-23
24470-0923-60 60 TABLET in 1 BOTTLE (24470-923-60) CHLORZOXAZONE Cintex Services, LLC 2021-09-23
31722-0974-01 100 TABLET in 1 BOTTLE (31722-974-01) CHLORZOXAZONE Camber Pharmaceuticals, Inc. 2025-03-20
31722-0974-05 500 TABLET in 1 BOTTLE (31722-974-05) CHLORZOXAZONE Camber Pharmaceuticals, Inc. 2025-03-20
31722-0974-10 1000 TABLET in 1 BOTTLE (31722-974-10) CHLORZOXAZONE Camber Pharmaceuticals, Inc. 2025-03-20
31722-0974-30 30 TABLET in 1 BOTTLE (31722-974-30) CHLORZOXAZONE Camber Pharmaceuticals, Inc. 2025-03-20
31722-0974-60 60 TABLET in 1 BOTTLE (31722-974-60) CHLORZOXAZONE Camber Pharmaceuticals, Inc. 2025-03-20
64980-0582-06 60 TABLET in 1 BOTTLE (64980-582-06) Chlorzoxazone Rising Pharma Holdings, Inc. 2023-08-09
69499-0330-60 60 TABLET in 1 BOTTLE, PLASTIC (69499-330-60) chlorzoxazone Solubiomix 2017-08-30
72336-0225-60 60 TABLET in 1 BOTTLE (72336-225-60) Chlorzoxazone Lifsa Drugs LLC 2025-03-20
87127-0801-60 60 TABLET in 1 BOTTLE (87127-801-60) CHLORZOXAZONE Happy Robin, LLC 2025-09-24
Observed labelers: Camber Pharmaceuticals, Inc. (5) · Cintex Services, LLC (2) · Happy Robin, LLC (1) · Lifsa Drugs LLC (1) · Rising Pharma Holdings, Inc. (1) · Solubiomix (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$2.5461
Range $2.5461–$2.5461 · middle 50% $2.5461–$2.5461 · 5 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.